Concepedia

Publication | Open Access

A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer

DOIFull Paper Access

63

Citations

17

References

2011

Year

Ivy Altomare, Johanna C. Bendell, Karen Bullock, Hope E. Uronis, Michael A. Morse, Shiaowen David Hsu, S. Yousuf Zafar, Gerard C. Blobe, Herbert Pang, Wanda Honeycutt,
The Oncologist

Abstract

Bevacizumab plus everolimus is generally tolerable but may have risks related to mucosal damage and/or wound healing. Bevacizumab plus everolimus appears to have modest activity in refractory mCRC in patients.

References

YearCitations

Page 1